Is Corbus Pharmaceuticals Holding (CRBP) overvalued? · $102.3M cap
Corbus Pharmaceuticals Holding (CRBP) is a biotechnology company listed on US.
This page asks whether Corbus Pharmaceuticals Holding (CRBP) looks expensive on cached numbers — not a short thesis.
Latest reported CRBP revenue for 2022-12-31 was $0. Net income was -$42.3M. CRBP currently screens at market cap $102.3M.
CRBP currently screens at market cap $102.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRBP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRBP stock page for the full model, not this heading.
Not investment advice.